Who
Matthew P. Young
Director
Company insider
Files Form 4 as: Director, CytomX Therapeutics; Director, PRA Health Sciences; EVP & CFO, Jazz Pharmaceuticals.
In numbers
- Trades disclosed
- 86
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $3.5M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 5 May 2014
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,000 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Jul 2021filed 1 Jul 2021 | PRA Health Sciences | SEC FORM 4 Code D | —7,127 | filing |
| 16 Jun 2021filed 17 Jun 2021 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 1 Jun 2021filed 3 Jun 2021 | PRA Health Sciences | SEC FORM 4 Code A | —250 at $0.00 | filing |
| 17 Jun 2020filed 17 Jun 2020 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 18 May 2020filed 20 May 2020 | PRA Health Sciences | SEC FORM 4 Code A | —1,324 at $0.00 | filing |
| 19 Jun 2019filed 21 Jun 2019 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 3 Jun 2019filed 5 Jun 2019 | PRA Health Sciences | SEC FORM 4 Code A | —1,436 at $0.00 | filing |
| 6 Mar 2019filed 7 Mar 2019 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $156K1,152 at $135.41 | filing |
| 5 Mar 2019filed 7 Mar 2019 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $172K1,267 at $135.82 | filing |
| 5 Mar 2019filed 7 Mar 2019 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $183K1,348 at $135.82 | filing |
| 28 Feb 2019filed 4 Mar 2019 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —714 at $0.00 | filing |
| 28 Feb 2019filed 4 Mar 2019 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —29,286 at $0.00 | filing |
| 28 Feb 2019filed 4 Mar 2019 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 27 Feb 2019filed 27 Feb 2019 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $122K884 at $137.91 | filing |
News
Jazz Pharmaceuticals gets Cramer's vote of confidenceJAZZ · aol.com · 14 Oct 2026Critical Analysis: vTv Therapeutics (NASDAQ:VTVT) and Jazz Pharmaceuticals (NASDAQ:JAZZ)JAZZ · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Matthew P. Young; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.